Canada · Delayed Price · Currency is CAD Devonian Health Group Company Description
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally.
It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis.
The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name.
Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Andre Boulet |
Contact Details
Address: 360, rue des Entrepreneurs Québec, QC G5V 4T1 Canada | |
| Phone | 581-632-0692 |
| Website | groupedevonian.com |
Stock Details
| Ticker Symbol | GSD |
| Exchange | TSX Venture Exchange |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| ISIN Number | CA2518341078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andre P. Boulet Ph.D. | Chair of the Board and Chief Executive Officer |
| Dennis Turpin CA, CPA | Chief Financial Officer and Director |
| Luc D. Gregoire CA, CPA | Executive Vice-President of Strategy |